Outsourcing lead optimisation - the quiet revolution

被引：24

作者：

Clark, DE ^{[1
]}

Newton, CG ^{[1
]}

机构：

[1] Argenta Discovery, Harlow CM19 5TR, Essex, England

来源：

DRUG DISCOVERY TODAY | 2004年 / 9卷 / 11期

关键词：

D O I：

10.1016/S1359-6446(04)03102-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The outsourcing of lead optimisation services is a relatively new but growing market. Historically, pharmaceutical companies have been hesitant to outsource activities at the lead optimisation stage of the drug discovery process, but more recently this reticence has largely been put aside. As a result, a growing number of companies with diverse backgrounds and geographical locations are now competing to offer services in this sector. Currently, a particularly significant trend is the move towards 'off-shoring', which promises to drive further changes in this rapidly evolving market in the near future.

引用

页码：492 / 500

页数：9

共 32 条

[1]

ALDRIDGE S, 2002, GENET ENG NEWS, V22, P13

[2]

BAXTER A.D., 2001, Drug Discovery World, V2, P9

[3]

BRUNO J, 2003, SCRIP MAGAZINE DEC, P20

[4] The extended pharmaceutical enterprise [J].

Cavalla, D .

DRUG DISCOVERY TODAY, 2003, 8 (06) :267-274

[5] Strategic trends in the drug industry [J].

Drews, J .

DRUG DISCOVERY TODAY, 2003, 8 (09) :411-420

[6]

GHANGURDE A, 2003, SCRIP MAGAZINE OCT, P31

[7]

KOPPAL T, 2003, DRUG DISCOV DEV DEC, P22

[8]

*MARK LEAD OPT TOO, 2003, KALORAMA INFORMA NOV, P5

[9]

*MARK LEAD OPT TOO, 2003, KALORAMA INFORMA NOV, P14

[10]

McCoy M, 2003, CHEM ENG NEWS, V81, P17

← 1 2 3 4 →